NCT05158023

Phase 2b Study of ASLAN004 in Adults With Moderate-to-Severe Atopic Dermatitis

A Randomized, Double-Blind, Placebo-Controlled, Multicenter, Dose-Ranging Trial to Evaluate the Efficacy and Safety of ASLAN004 in Adult Patients With Moderate-to-Severe Atopic Dermatitis

• Status: Completed
• Phase: Phase 2
• Study type: Interventional
• Enrollment: 302 (actual)
• Sponsor: ASLAN Pharmaceuticals · Academic / Other
• Sex: All
• Age: 18 Years
• Healthy volunteers: Not accepted

Summary

Phase 2b study designed to evaluate the efficacy and safety of ASLAN004 in adult patients with moderate-to-severe Atopic Dermatitis (AD) who are candidates for systemic therapy. This study will have 5 treatment arms (4 active and 1 placebo).

Conditions

• Atopic Dermatitis

Interventions

Type	Name	Description
DRUG	Placebo Comparator	Sterile solution for subcutaneous injection
BIOLOGICAL	ASLAN004	Sterile solution for subcutaneous injection
BIOLOGICAL	ASLAN004	Sterile solution for subcutaneous injection
BIOLOGICAL	ASLAN004	Sterile solution for subcutaneous injection
BIOLOGICAL	ASLAN004	Sterile solution for subcutaneous injection

Timeline

• Start date: 2022-03-16
• Primary completion: 2023-06-13
• Completion: 2023-09-05
• First posted: 2021-12-15
• Last updated: 2024-04-26

Locations

83 sites across 8 countries: United States, Australia, Canada, Dominican Republic, India, New Zealand, Poland, Singapore

Regulatory

• FDA-regulated drug study